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Introduction
The CD8 T cells are key players in the immune response to intra-
cellular infections and tumours. Recognition of any intracellular or
viral protein by CD8 cytotoxic T lymphocytes requires an initial
cytosolic proteolytic processing by proteasomes to peptide prod-
ucts, which are then translocated by transporters associated with
antigen processing (TAP) into the endoplasmic reticulum (ER),
where they assemble with major histocompatibility complex
(MHC) class I molecules to be presented to the cell surface [1].
Most peptides released from the proteasome into the cytosol
are promptly degraded by cytosolic endopetidases and aminopep-
tidases to single amino acids before they can ‘escape’ by binding to
the TAP and enter the ER. It has been calculated that only one pep-
tide binds to an MHC class I molecule from 104 degraded proteins
[2]. This explains the relatively subtle efficiency of antigen presen-
tation by class I molecules. Coupled with this, cervical cancer cells
(as well as a number of other malignant tumours) often show down
regulation or, in a subset of cases, complete loss of MHC class I
expression, most likely as a mechanism of immune escape [3].
Previous studies have shown that antigens linked to Calreticulin
(CRT), an abundant 46 kD Ca2-binding protein located in the ER,
are directly expressed in the ER, avoiding cytoplasmic degradation
[4]. In this way all antigen molecules would be available for degra-
dation into the ER and a larger number of peptides might be
 generated to be loaded onto MHC-I. With this strategy, peptide-
specific CD8 T-cell responses and antigen-antitumour activity
against a murine model of cervical uterine cancer were enhanced
by fusion of the human papilloma virus (HPV-16) antigen E7 to CRT
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Abstract
The endoplasmic reticulum (ER) is where the major histocompatibility complex (MHC) class I molecules are loaded with epitopes to
cause an immune cellular response. Most of the protein antigens are degraded in the cytoplasm to amino acids and few epitopes reach
the ER. Antigen targeting of this organelle by Calreticulin (CRT) fusion avoids this degradation and enhances the immune response. We
constructed a recombinant adenovirus to express the E7 antigen with an ER-targeting signal peptide (SP) plus an ER retention signal
(KDEL sequence). In cell-culture experiments we demonstrated that this new E7 antigen, SP-E7-KDEL, targeted the ER. Infection of mice
with this recombinant adenovirus that expresses SP-E7-KDEL showed interferon induction and tumour-protection response, similar to
that provided by an adenovirus expressing the E7 antigen fused to CRT. This work demonstrated that just by adding a SP and the KDEL
sequence, antigens can be targeted and retained in the ER with a consequent enhancement of immune response and tumour protection.
These results will have significant clinical applications.
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[4, 5]; however, the mechanism involved remains poorly under-
stood. More significantly, the CRT has been shown to generate the
greatest immune response compared to other adjuvant fusions,
such as the sorting signal of the lysosome-associated membrane
protein, Mycobacterium tuberculosis heat-shock protein 70
(HSP70) and the translocation domain of Pseudomonas aeruginosa
exotoxin A. To simplify this strategy and to determine if most of the
antitumour properties conferred by calreticulin are dependent on its
ability to be retained in the ER, we engineered a new version of an
E7 gene bearing the signals required for ER targeting, signal peptide
(SP: MLLPVPLLLGLLGLAAAL) and ER retention (KDEL).
We have previously shown that vaccination with an adenovirus
expressing CRT chimerically linked to the HPV-16 E7 antigen causes
stronger E7-specific immune responses compared to vaccination
with an adenovirus vector expressing only the E7 protein [6].
Herein, we constructed an adenovirus expressing the E7 anti-
gen with a SP at its amino end and a KDEL sequence at its carboxyl
end (Fig. 1A) (For details on adenoviral constructs see Supporting
Information). After adenovirus production, human embryonic kid-
ney 293 (HEK293) cells were infected with the different aden-
oviruses (SP-E7-KDEL, CRT-E7 or LacZ), and the protein extracts
were analysed by Western blot. As shown in Fig. 1B, the SP-E7-
KDEL adenovirus expresses an 18 kD protein, as expected, in
 contrast to the 70 kD band expressed by the CRT-E7 adenovirus.
To demonstrate that the SP-E7-KDEL fusion protein has been
Fig. 1 Generation of an adenovirus expressing SP-E7-KDEL. (A) Graphic
representation of the gene constructs. Fusion of the HPV16 E7 protein
and different signal sequences was made in silico and then gen synthe-
sized. (B) Detection of the SP-E7-KDEL and CRT-E7 protein expression
by Western blot. HEK293 cells were infected with the adenovirus
expressing SP-E7-KDEL, CRT-E7, and LacZ at a multiplicity of infection
(MOI) of 10. Twenty-four hours after infection cell-protein extracts were
prepared and subjected to SDS-PAGE electrophoresis, and transferred to
nitrocellulose membranes. These were incubated first with a monoclonal
antibody against HPV16 E7 protein, then with the rabbit antimouse 
IgG-HRP second antibody, and developed with Super Signal West Pico
stable peroxide solution.
Fig. 2 Distribution of the
proteins SP-E7-KDEL and
CRT-E7 to the ER. HEK293
cells infected at a MOI 
of 5 with an adenovirus
expressing SP-E7-KDEL,
Ad-CRT-E7 or LacZ, were
cultured over glass slides
for 48 hrs. Cells were fixed
and first incubated with
rabbit anti-calnexin MAb or
mouse anti-E7, and then
with AlexaFluor 488-conju-
gated goat anti-rabbit IgG
or AlexaFluor594-conju-
gated goat antimouse. The
glass slides were mounted
with antifading medium,
Vectashield with DAPI, and
covered with cover slips.
Samples were examined 
by using a fluorescence
microscope.
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 distributed to the ER, we did immunofluorescent staining of cells
infected with the different adenoviruses using antibodies against
E7 protein and calnexin (a well-characterized marker for the ER)
[7]. Previous studies in our laboratory and by others have demon-
strated that the cytoplasmic/nuclear localization of E7 is lost by
fusion to calreticulin which sequesters E7 to the ER [4–6]. As
shown here again in Fig. 2, E7 (red signal) colocalization with the
calnexin protein (green signal) confirms the distribution of the
CRT-E7 to the ER. Similarly, E7 bearing the SP and the ER retention
sequence from CRT (SP-E7-KDEL) had the same pattern as the cal-
nexin marker, demonstrating that the signal sequences added to E7
from CRT are able to replace its function of ER retention.
To evaluate if the SP and KDEL signals have the same adjuvant
effect as CRT did with E7, groups of female adult C57BL6 mice
treated with adenovirus expressing either the SP-E7-KDEL or CRT-
E7 were analysed for levels of interferon (IFN)-, a signature
cytokine for Th1 responses and the effector function of CD8 T
cells, critical for tumour eradication [4–6]. We previously had
shown that fusion of CRT to E7 increases, about five times, the
release of IFN- from splenocytes of mice immunized with an
Adenovirus expressing this fusion (50 pg/ml) versus an
Adenovirus expressing just E7 (10 pg/ml), and increases this eight
times versus and Adenovirus expressing LacZ (6 pg/ml) [6]. As
shown in Fig. 3, we confirmed again that splenocytes from mice
immunized with Ad-CRT-E7 generated significant levels of IFN-
when stimulated in vitro by the E7 epitope. The IFN- response
upon immunization with the adenovirus expressing the SP-E7-
KDEL showed also a significant induction of IFN- as the Ad-CRT-
E7 did (eight times over the control Ad-LacZ).
We then evaluated the protective effect of these chimeric pro-
teins in a murine tumoral model. For this purpose, groups of
female adult C57BL6 mice were challenged with HPV-16 E7-
expressing murine tumour cells, designated TC-1, 1 week after
immunization with adenovirus expressing CRT-E7, SP-E7-KDEL,
E7 or LacZ. As seen in Fig. 4, rapid tumour growth was observed
in the group of mice immunized with the control adenovirus
expressing LacZ, all of whom had to be killed. As expected, immu-
nization with an Adenovirus expressing E7 did no protect the mice
against tumour development, which is because of its poor
immunogenicity [4–6]. All the mice had to be killed as well. In con-
trast, all the mice vaccinated with the adenovirus expressing SP-
E7-KDEL or CRT-E7 eliminated the tumour. This similar protective
effect demonstrates that the SP and KDEL signals are enough to
enhance the antitumour immune response.
Taken together, our results indicate that the adjuvant antitu-
mour effect attributed to CRT [8–12] is mainly conferred by its SP
and KDEL sequences, which allow antigens to enter and be main-
tained in the ER. The KDEL sequence is emerging as a significant
antitumour immunity sequence. Recently, it was shown that den-
dritic cells loaded with exogenous peptides bearing the KDEL
motif showed a more efficient antitumour activity than dendritic
cells pulsed with peptides without KDEL [13]. Even though the
mechanism of epitope generation in the ER is poorly understood,
the KDEL sequence might result in a longer trafficking time
through the ER, increasing the possibility of degradation and 
consequently, peptide generation and loading by the MHC-1 mol-
ecule. It will be worth determining the contribution of the SP itself
to the adjuvant effect compared to the addition of both SP and
KDEL sequences [14, 15]. Another advantage of this strategy is to
Fig. 3 Detection of IFN- induction by ELISA. Groups of three mice were
immunized by intraperitoneal (ip) injection with adenovirus expressing
SP-E7-KDEL, CRT-E7 or LacZ (5  1010 VPs/mouse). Splenocytes from
these animals were harvested after 7 days, and then stimulated in vitro
with the E7 CTL immunodominant epitope RAHYNIVTF (amino acids
49–57) for 3 days. The culture supernatants were collected and levels of
IFN- were determined using the IFN- ELISA kit, according to the man-
ufacturer’s protocol. The basal levels of IFN, without peptide stimulation,
were substracted. *P  0.05, compared against controls LacZ and PBS.
Fig. 4 Tumour protection assay. Groups of five mice were vaccinated by
ip injection with 5  1010 VPs/mouse of adenovirus expressing SP-E7-
KDEL, CRT-E7, E7 or LacZ. One week later, mice were subcutaneously
(sc) challenged with 5  104 TC-1 cells in the right leg. Tumour growth
was monitored twice a week with a calliper. Tumour size was expressed
as the mean of two perpendicular diameters. Values and bars represent
the mean and Standard Error of tumour size. Ad-CRT-E7 and Ad-SP-E7-
KDEL are statistically different from Ad-E7 and Ad-LacZ (*P  0.05).
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prevent any putative adverse effect caused by overexpression of
CRT, because of, for example its role in Ca2 storage and trans-
port into the ER [16]. It has been demonstrated that fusion of CRT
also enhances the humoral response of antigens such as the
receptor-binding domain (domain IV) of the protective antigen
(PA[dIV]) of Bacillus anthracis [17] and a SARS coronavirus anti-
gen [18]. Even though the pathway is unknown, it is expected that
our strategy might potentiate this response as well. In conclusion
targeting of antigens to the ER confers a striking immunogenic
potential in gene cancer therapy. This work represents an impor-
tant contribution for basic research and future clinical translation.
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Supporting Information
Materials and methods
Mice. Female C57BL6 mice (6–8 weeks old) were purchased from
Harlan (México City, México), housed in the animal facilities of the
Histology Department of the School of Medicine, UANL, and cared
for in conformity with good laboratory practice guidelines.
Cell lines. HEK293 cells were maintained in advanced DMEM
 supplemented with 4% heat-inactivated foetal bovine serum (FBS).
TC-1 cells derived from primary epithelial cells of C57BL/6 mice
co-transformed with HPV-16 E6 and E7 and the c-Ha-ras onco-
genes, were maintained in RPMI 1640 medium supplemented with
10% heat-inactivated FBS. All of the cell lines were purchased from
American Type Culture Collection (Manassas, VA, USA).
Adenovirus. Fusion of the HPV16 E7 protein and different signal
sequences was done in silico and then synthesized by the GenArt
Company. Genes were subcloned in pShuttle vector and then
recombined with the adenoviral genome. Replication- deficient 
E1  E3-deleted adenovirus containing the gene of interest was
amplified in 293 cells. Infected cells were harvested and lysed, and
the viral particles (VPs) were purified using the ViraBind
Adenovirus Purification kit (Cell Biolabs, Inc., San Diego, CA, USA).
Western blot. HEK293 (2  105) cells were plated in 12-well
plates and infected the next day with the different adenoviruses to
be tested (MOI 10). Twenty-four hours after infection cells were
lysed with ProteoJet Mammalian Lysis Solution (Fermentas).
Lysed cells, mixed with 30 l 2 SDS loading buffer, were heated
at 100C for 5 min., and centrifuged at 13,000 rpm for 10 min.
Protein samples were separated by electrophoresis gel and trans-
ferred to nitrocellulose membranes. The membranes were blocked
for 1 hr with 10% non-fat dry milk in TBST (135 mM NaCl, 2.7 mM
KCl, 24.8 mM TRIS.HCl, 0.05% Tween 20, pH 7.4) and then
probed with an antibody in TBST for 1 hr at 25 C. A monoclonal
antibody against HPV16 E7 protein (Zymed) was used to probe
the expression of E7. Blots were rinsed with TBST, incubated with
rabbit antimouse IgG-HRP second antibody (Sigma) for 1 hr, then
rinsed with TBST again, and developed with Super Signal West
Pico stable peroxide solution (Pierce).
Immunofluorescence. HEK293 cells infected at a MOI of 5 with
Ad-LacZ, Ad-CRT-E7 or Ad-SP-E7-KDEL were cultured over glass
slides for 48 hrs. Cells were washed in PBS, and fixed with a
methanol:acetone solution for 10 min at –20 C; blocked with a
2% BSA in PBS solution, and then incubated with rabbit anti-cal-
nexin MAb (Santa Cruz Bio-technology) or mouse anti-E7 (Zymed)
at a concentration of 1 g/ml for 1 hr at room temperature. After
several washes with PBS, cells were incubated with AlexaFluor
488-conjugated goat anti-rabbit IgG or AlexaFluor 594-conjugated
goat antimouse (Invitrogen) at a concentration of 10 g/ml for 1 hr.
The slides were then washed with PBS containing 1% BSA and
mounted with antifading medium, Vectashield with DAPI (Vector),
and covered with cover slips. Samples were examined by using a
Leica fluorescence microscope.
Detection of IFN-. Groups of three mice were immunized by
intraperitoneal (ip) injection with adenovirus expressing SP-E7-
KDEL, CRT-E7 or LacZ (5  1010 VPs/mouse). Splenocytes from
these animals were harvested after 7 days and were stimulated
with E7 CTL immunodominant epitope RAHYNIVTF (amino acids
49–57) in 24-well plates for 3 days. Culture supernatants were
collected and levels of IFN- were determined using an IFN-
ELISA kit (R&D) according to the manufacturer’s protocol. Data
are representative of two experiments.
Tumour protection assay. Groups of five mice were vaccinated by
ip injection with 5  1010 VPs/mouse of adenovirus expressing
SP-E7-KDEL, CRT-E7 or LacZ. One week later, mice were 
subcutaneously (sc) challenged with 5  104 TC-1 cells in the
right leg. Tumour growth was monitored twice a week with a cal-
liper. The tumour size was expressed as the mean of two perpen-
dicular diameters. Values and bars represent the mean and stan-
dard error of tumour size. Animals bearing tumours were killed at
day 28. Data are representative of two experiments.
Statistical analysis. Statistical analysis was done using an ANOVA
test. P-values  0.05 were considered significant.
Please note: Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to the
corresponding author for the article.
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